Boston Scientific won FDA regulatory approval to introduce the Eluvia drug-eluting vascular stent to the U.S. market. The device is the first peripheral stent to offer sustained release of an antiproliferative drug (paclitaxel) for as long as a full year. The drug prevents restenosis, a common condition caused by native tissue growing over the ste (Read more...)